Police looking for a man accused of stalking two children in New York City -- following the kids and delivering a creepy note to their family -- may have a break in the case, Fox 5 New York reported.
NYS Entity Status
NYS Filing Date
AUGUST 14, 2014
NYS DOS ID#
NYS Entity Type
FOREIGN NOT-FOR-PROFIT CORPORATION
2014 - OANDO FOUNDATION US
Around the Web
- NY family gets creepy note from apparent stalker: 'Your daughter is cute'
Monday Oct 23, 2017
- Hainan Cihang Charity Foundation Won’t Solicit Funds in New York
By firstname.lastname@example.org (Kyoko Uchida) - Monday Aug 7, 2017
The U.S. charity of a Chinese conglomerate that has come under scrutiny has stated that it will not solicit funds in the state, but it will register as a nonprofit that holds, rather than solicits, funds....
- For Parkinson’s, Two New Drugs Coming As Prevail Gets Started in NY
By Ben Fidler - Wednesday Aug 9, 2017
A drug that actually slows or reverses the brain damage inflicted by Parkinson’s disease, rather than just alleviates its often debilitating symptoms, remains elusive. But Prevail Therapeutics, a startup just launched in New York, has become the latest to try. This morning, the Silverstein Foundation, a nonprofit organization formed by OrbiMed partner Jonathan Silverstein, announced […]
- Alexandria Debuts NY’s Latest Bio Incubator With 13 Startups in Tow
By Ben Fidler - Tuesday Jun 13, 2017
A new startup incubator has just opened in Manhattan this morning, adding to a growing list of facilities meant to help support seedling New York City biotechs. LaunchLabs, first announced by Alexandria Real Estate Equities a year ago, officially opened its doors and revealed the 13 startups that will grow there. LaunchLabs is a 15,000-square-foot […]
- Acorda Scraps One Parkinson’s Drug, Puts Its Cash Behind Another
By Frank Vinluan - Monday Nov 20, 2017
Acorda Therapeutics said Monday that it will stop work on an experimental treatment for Parkinson’s disease, spelling the end for a drug the Ardsley, NY, company added to its pipeline last year in a $363 million deal. The announcement follows the recent emergence of safety problems for the Acorda (NASDAQ: ACOR) drug, tozadenant. Acorda said […]